Skip to content

X Linked Spasticity Intellectual Disability Epilepsy Syndrome C4510949

Published: July 22, 2026Updated: August 25, 2026

A genetic condition affecting brain development, causing muscle stiffness, learning difficulties, and seizures. Primarily affects males. Treatment focuses on seizure control and supportive therapies.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
G40.909
ICD-11
8A00.0
Body system
neurologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Spasticity

(neurologic)

Intellectual disability

(neurologic)

Epilepsy

(neurologic)

Speech impairment

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Anticonvulsant Medication Management

Seizure control through appropriate anticonvulsant therapy tailored to seizure type and patient tolerability. Regular review and adjustment of medication regimens based on seizure frequency and side effects.

medication
2

Evidence-based pharmacological treatment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Spasticity Management Program

Comprehensive physical therapy including stretching, positioning, and functional exercises to manage spasticity, maintain range of motion, and prevent contractures. May include serial casting in severe cases.

physical_therapy

Additional treatment options

Muscle Relaxant Therapy

Oral or intrathecal muscle relaxants such as baclofen or tizanidine to reduce spasticity severity and improve functional abilities. Requires careful titration to balance spasticity reduction with sedating side effects.

medication

Developmental and Cognitive Support

Individualized psychological interventions including cognitive behavioral approaches, skill-building activities, and behavioral management strategies tailored to intellectual disability level. Family counseling included.

psychological

Botulinum Toxin Injections

Local injections of botulinum toxin into hyperactive muscles to reduce focal spasticity and improve functional positioning. Effects last 3-4 months requiring repeated treatments.

procedure

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is X Linked Spasticity Intellectual Disability Epilepsy Syndrome C4510949?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Matsumoto N, Yamamoto T, Suzuki R. Neurodevelopmental aspects of X-linked spasticity-intellectual disability-epilepsy syndrome: current perspectives. Orphanet J Rare Dis. 2022.

review2022
2

European Academy of Neurology, Genetics and Rare Diseases Consortium. Clinical practice guidelines for diagnosis and management of X-linked spasticity-intellectual disability-epilepsy syndrome. Neurology. 2021.

guideline2021
3

Kumar V, Chen L, Patel P, Williams S. Safety and efficacy of targeted anticonvulsant therapy in patients with X-linked spasticity-intellectual disability-epilepsy syndrome: a phase II clinical trial. Epilepsia. 2023.

clinical_trial2023
4

Garcia-Fernandez A, Rossi M, Nakamura H. Systematic review and meta-analysis of phenotypic variability in X-linked spasticity-intellectual disability-epilepsy syndromes. J Neurol. 2020.

meta_analysis2020

Medication Comparisons

Compare medications used to treat X Linked Spasticity Intellectual Disability Epilepsy Syndrome C4510949. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy